Achievement of optimal combined lipid values in a managed care setting: Is a new treatment paradigm needed?

Clinical Therapeutics

Volumn 29, Issue 1, 2007, Pages 196-209

  Sarawate, Chaitanya A ^a   Cziraky, Mark J ^a   Stanek, Eric J ^b   Willey, Vincent J ^a   Corbelli, John C ^c   Charland, Scott L ^b,d  

^a HEALTHCORE INC   (United States)

^b Kos Pharmaceuticals Inc   (United States)

^c Cardiology Associates   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

cardiovascular diseases; cholesterol; clinical practice; dyslipidemia; lipids; lipoproteins; macrovascular

Indexed keywords

ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CORONARY RISK; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MONOTHERAPY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; CORONARY DISEASE; ENDPOINT DETERMINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LONGITUDINAL STUDIES; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINES; PRIMARY PREVENTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES;

EID: 33947217299     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.01.004     Document Type: Article

References (52)

1. [published correction appears in Circulation. 2006;113:e696]. Thom T., Haase N., Rosamond W., et al., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113 (2006) e85-e151
2. Ford E.S., Mokdad A.H., Giles W.H., and Mensah G.A. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: Findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 107 (2003) 2185-2189
3. Yusuf S., Hawken S., Ounpuu S., et al., INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): Case-control study. Lancet 364 (2004) 937-952
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360 (2002) 7-22
6. American Heart Association. Heart Disease and Stroke Statistics-2005 Update (2005), American Heart Association, Dallas, Tex
7. Waters D.D., Guyton J.R., Herrington D.M., et al., TNT Steering Committee Members and Investigators. Treating to New Targets (TNT) Study: Does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. Am J Cardiol 93 (2004) 154-158
8. Assmann G., Schulte H., Funke H., and von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 19 Suppl M (1998) M8-M14
9. Gordon D.J., Probstfeld J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
10. Kannel W.B. High-density lipoproteins: Epidemiologic profile and risks of coronary artery disease. Am J Cardiol 52 (1983) 9B-12B
11. Sharrett A.R., Ballantyne C.M., Coady S.A., et al., Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cho lesterol levels, triglycerides, lipoprotein (a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104 (2001) 1108-1113
12. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
13. [published correction appears in Lancet. 2005;366:1358]. Baigent C., Keech A., Kearney P.M., et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
14. Blankenhorn D.H. Prevention or reversal of atherosclerosis: Review of current evidence. Am J Cardiol 63 (1989) 38H-41H
15. Fuke D., Hunt J., Siemienczuk J., et al. Cholesterol management of patients with diabetes in a primary care practice-based research network. Am J Manag Care 10 (2004) 130-136
16. Sever P.S., Dahlof B., Poulter N.R., et al., ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
17. Shepherd J., Blauw G.J., Murphy M.B., et al., PROSPER Study Group (PROspective Study of Pravastatin in the Elderly at Risk). Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 360 (2002) 1623-1630
18. Brown B.G. Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy. Eur Heart J Suppl 7 Suppl F (2005) F34-F40
19. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
20. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323 (1990) 1289-1298
21. Taylor A.J., Lee H.J., and Sullenberger L.E. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 22 (2006) 2243-2250
22. [published corrections appear in Circulation. 2004;110:3615 and Circulation.2005;111:e446]. Taylor A.J., Sullenberger L.E., Lee H.J., et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
23. Saseen J.J., Williams S.A., Valuck R.J., et al. The performance gap between clinical trials and patient treatment for dyslipidemia: A comprehensive review. Dis Manag Health Outcomes 13 (2005) 255-265
24. Frolkis J.P., Zyzanski S.J., Schwartz J.M., and Suhan P.S. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation 98 (1998) 851-855
25. Olson K.L., Rasmussen J., Sandhoff B.G., et al., Clinical Pharmacy Cardiac Risk Service Study Group. Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization. Arch Intern Med 165 (2005) 49-54
26. Garcia Ruiz F.J., Marin Ibanez A., PerezJimenez F., et al., REALITY Study Group. Current lipid management and low cholesterol goal attainment in common daily practice in Spain: The REALITY study. PharmacoEconomics 22 Suppl 3 (2004) 1-12
27. International Classification of Diseases, Ninth Revision, Clinical Modification (1995), US Dept of Health and Human Services, Hyattsville, Md
28. Bullano M.F., Kamat S., Willey V.J., et al. Agreement between administrative claims and the medical record in identifying patients with a diagnosis of hypertension. Med Care 44 (2006) 486-490
29. Deyo R.A., Cherkin D.C., and Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM admin istrative databases. J Clin Epidemiol 45 (1992) 613-619
30. Hebert P.L., Geiss L.S., Tierney E.F., et al. Identifying persons with diabetes using Medicare claims data. Am J Med Qual 14 (1999) 270-277
31. Yu Y., Bullano M.F., and Willey V.J. Evaluating the diagnostic validity of administrative claims data for com mon chronic diseases. Value Health 8 (2005) 267
32. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40 (1987) 373-383
33. Bernardini J., Callen S., Fried L., and Piraino B. Inter-rater reliability and annual restoring of the Charlson co morbidity index. Adv Perit Dial 20 1 (2004) 25-127
34. Streiner D.L. The case of the missing data: Methods of dealing with dropouts and other research vagaries. Cant Psychiatry 47 (2002) 68-75
35. White H. A heteroskedasticityconsistent covariance matrix estimator and a direct test for hetero skedasticity. Econometrica 48 (1980) 817-838
36. Hosmer D.W., Hosmer T., Le Cessie S., and Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med. 16 (1997) 965-980
37. Abookire S.A., Karson A.S., Fiskio J., and Bates D.W. Use and monitoring of "statin" lipid-lowering drugs com pared with guidelines. Arch Intern Med 161 (2001) 53-58
38. Bozovich M., Rubino C.M., and Edmunds J. Effect of a clinical pharmacistmanaged lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. Pharmacotherapy 20 (2000) 1375-1383
39. LaBresh K.A., Owen P., Alteri C., et al. Secondary prevention in a cardiology group practice and hospital set ting after a heart-care initiative. Am J Cardiol 85 (2000) 23A-29A
40. Lai L.L., Poblet M., and Bello C. Are patients with hyperlipidemia being treated? Investigation of cholesterol treatment practices in an HMO primary care setting. South Med J. 93 (2000) 283-286
41. Latts L.M. Assessing the results: Phase 1 hyperlipidemia outcomes in 27 health plans. Am J Med 110 Suppl 6A (2001) 17S-235
42. Malach M., Quinley J., Imperato P.J., and Wallen M. Improving lipid evaluation and management in Medicare patients hospitalized for acute myocardial infarction. Arch Intern Med 161 (2001) 839-844
43. McBride P., Schrott H.G., Plane M.B., et al. Primary care practice adherence to National Cholesterol Edu cation Program guidelines for patients with coronary heart disease. Arch Intern Med 158 (1998) 1238-1244
44. Merenich J.A., Lousberg T.R., Brennan S.H., and Calonge N.B. Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed-care environment (the Rocky Mountain Kaiser Permanente experience). Am J Cardiol 85 (2000) 36A-42A
45. Pearson T.A., Laurora I., Chu H., and Kafonek S. The Lipid Treatment Assessment Project (L-TAP): A mul ticenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160 (2000) 459-467
46. Qureshi A.I., Suri M.F., Guterman L.R., and Hopkins L.N. Ineffective secondary prevention in survivors of cardiovas cular events in the US population: Report from the Third National Health and Nutrition Examination Survey. Arch Intern Med 161 (2001) 1621-1628
47. Robinson J.G., Conroy C., and Wickemeyer W.J. A novel telephone-based system for management of secondary pre vention to a low-density lipoprotein cholesterol < or = 100 mg/dL. Am J Cardiol 85 (2000) 305-308
48. Chapman M.J., Assmann G., Fruchart J.C., et al., European Consensus Panel on HDLC. Raising high density lipoprotein cholesterol with reduction of cardiovascular risk: The role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 20 (2004) 1253-1268
49. Grundy S.M., Cleeman J.I., Merz C.N., et al., Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 44 (2004) 720-732
50. Mosca L., Appel L.J., Benjamin E.J., et al., American Heart Association. Evidence-based guidelines for cardiovascular disease prevention in women. American Heart Association scientific statement. Arterioscler Thromb Vasc Biol 24 (2004) e29-e50
51. Mosca L., Merz N.B., Blumenthal R.S., et al. Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting. Circulation 111 (2005) 488-493
52. [published correction appears in N Engl J Med. 2006;354:778]. Cannon C.P., Braunwald E., McCabe C.H., et al., Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504